Prospect Capital books $328 million exit, gives PSEC stock a new driver
Prospect Capital shares rose 2.1% to $2.37 after announcing the sale of Valley Electric to MYR
Atlas Critical Minerals Stock Faces a New Test as Defense-Metals Money Rushes Into Nasdaq
Atlas Critical Minerals Corp’s U.S. shares closed Thursday at $4.41, near a 52-week low, with after-hours trading at $4.36. The company raised about $11 million in its January Nasdaq debut, controlling over
Solid Power Shares on the Move Again; Battery Bulls Eye $3.40
Solid Power shares traded at $3.40, up 1.2% Thursday afternoon on the Nasdaq, with volume near 4 million and market cap around $739 million. Investors watched updates on SK On work and cash position, as the company reported $3.1 million in Q1 revenue and $435.3 million in liquidity. Peers QuantumScape and SES AI also rose. Solid Power focuses on selling solid electrolyte material and licensing its battery tech.
Viking Therapeutics Stock Draws Wall Street Attention with Obesity Pill Competition Growing
Viking Therapeutics shares rose 1.7% to $32.19 after Lake Street initiated coverage with a Buy rating and an $89 price target, citing potential for its obesity drug VK2735. Phase 2 trial data showed up to 12.2% mean weight loss in 13 weeks. The company’s market cap stood at $3.72 billion. Board elections and auditor approval were disclosed in a May 26 SEC filing.
MapLight Stock Slips Ahead of August Drug Update
MapLight Therapeutics shares fell 1.3% to $29.17 Thursday as investors awaited Phase 2 trial results for schizophrenia and autism, expected by mid-August. The company finished enrolling 307 patients in its ZEPHYR schizophrenia study and ended March with $395.2 million in cash. Analyst price targets ranged from $28 to $48. MapLight’s lead drug targets muscarinic receptors, a newer approach in antipsychotic treatment.
Peraso Stock Pops 13% as PRSO Traders Bet a Delayed Order Is Finally Behind It
Peraso Inc. shares rose about 13% Thursday, trading near $1.165 on volume of 1.29 million after closing at $1.03. The move followed weak first-quarter results, with net revenue down to $963,000 from $3.87 million a year earlier and a net loss widening to $2.5 million. Management said a delayed customer order has now shipped. No new company disclosures were issued Thursday.
New Fortress Energy Shares Dip Under 60 Cents Ahead of Key Reverse-Split Vote
New Fortress Energy Inc. fell to 55.79 cents early Thursday, down 3.8%, with a market value near $159 million after releasing its annual meeting proxy. The company faces possible Nasdaq delisting after months below $1 per share and reported a Q1 net loss of $399.95 million on $226.95 million revenue. Debt stood at $8.29 billion as of March 31, with most classified as current due to defaults. Shareholders will vote June 17 on a 1-for-50 reverse split and restructuring plan.
Big Digital Energy Stock Drops as Its AI-Power Pivot Runs Into a Cash Test
Big Digital Energy Inc. shares fell 20 cents to $6.46 in Nasdaq trading Thursday, underperforming larger bitcoin-mining peers. The company reported Q1 revenue dropped to $4.8 million from $13.8 million a year earlier, with operations losing $8.2 million and cash use of $17.1 million. Big Digital ended March with $2.4 million in cash and warned of “substantial doubt” about its ability to continue as a going concern.
Satellogic stock pops on $18 million injection, 10 million-share filing appears
Satellogic Inc. rose 1.6% to $9.93 Thursday after announcing an $18 million, one-year defense contract and a major shareholder’s plan to sell 10 million shares. The stock traded between $9.47 and $10.11, with market cap near $1.40 billion. First-quarter revenue climbed 80% to $6.1 million, and the company reported positive operating cash flow. Liberty Strategic Capital filed notice to sell shares worth $97.7 million.
Moderna Shares Dip With FDA Vote Putting COVID Vaccine Plan to Test
Moderna shares fell 2.6% to $46.39 Thursday as an FDA advisory panel met to discuss the 2026-2027 COVID-19 vaccine formula, focusing on the XFG strain. The company reported a Q1 net loss of $1.3 billion and $389 million in revenue, mostly outside the U.S. FDA advisers will review Moderna’s mRNA flu shot for older adults on June 18. Wall Street analysts remain divided on the stock’s outlook.
Big Digital Energy Stock Drops as Its AI-Power Pivot Runs Into a Cash Test
Big Digital Energy Inc. shares fell 20 cents to $6.46 in Nasdaq trading Thursday, underperforming larger bitcoin-mining peers. The company reported Q1 revenue dropped to $4.8 million from $13.8 million a year earlier, with operations losing $8.2 million and cash use of $17.1 million. Big Digital ended March with $2.4 million in cash and warned of “substantial doubt” about its ability to continue as a going concern.
Satellogic stock pops on $18 million injection, 10 million-share filing appears
Satellogic Inc. rose 1.6% to $9.93 Thursday after announcing an $18 million, one-year defense contract and a major shareholder’s plan to sell 10 million shares. The stock traded between $9.47 and $10.11, with market cap near $1.40 billion. First-quarter revenue climbed 80% to $6.1 million, and the company reported positive operating cash flow. Liberty Strategic Capital filed notice to sell shares worth $97.7 million.
Moderna Shares Dip With FDA Vote Putting COVID Vaccine Plan to Test
Moderna shares fell 2.6% to $46.39 Thursday as an FDA advisory panel met to discuss the 2026-2027 COVID-19 vaccine formula, focusing on the XFG strain. The company reported a Q1 net loss of $1.3 billion and $389 million in revenue, mostly outside the U.S. FDA advisers will review Moderna’s mRNA flu shot for older adults on June 18. Wall Street analysts remain divided on the stock’s outlook.
Xerox pops after 15 million-share filing seen as turnaround signal
C4 Therapeutics shares traded at $3.74 before the Nasdaq open on May 28, holding gains after a 7.16% rise the prior session. The move comes as investors await cemsidomide updates at ASCO and EHA meetings. C4 reported $268.3 million in cash at March 31 and a narrowed Q1 net loss. The company expanded its Roche partnership in April, securing a $20 million upfront payment.
NewAmsterdam Pharma Stock Rises as Fresh Filing Puts Its $4.3 Billion Drug Bet in Focus
NewAmsterdam Pharma shares rose 1.3% to $36.56 Wednesday after Chief Accounting Officer Louise Frederika Kooij exercised and sold 65,000 shares, according to a Form 4 filing. A separate Form 144 listed a proposed sale of 210,000 shares for Kooij. The company awaits key regulatory decisions on its cholesterol drug obicetrapib later this year. NewAmsterdam reported a first-quarter net loss of $48.4 million.
Segg Gains 12% as Jane Street Stake Tangles With Nasdaq Filing
Sports Entertainment Gaming Global Corp. shares rose 12.1% to $1.57 Wednesday after Jane Street disclosed a 5.5% stake. SEGG remains out of Nasdaq compliance due to a late quarterly filing and has 60 days to submit a plan. The company is shifting focus from Lottery.com to sports, media, and gaming. About 1.35 million shares traded Wednesday.
AppLovin Pops Back Over $600 as Wall Street Watches Key Ad Number
AppLovin shares rose 2.0% to $612.07 late Friday, outpacing the broader market. Morgan Stanley maintained its Overweight rating and $720 target, citing potential gains from higher ad-conversion rates. The company reported Q1 revenue up 59% to $1.84 billion and plans to open its Axon platform to more advertisers in June.
Axcelis Drops Even as Chip Stocks Surge: Street Focuses on Next Move
Axcelis Technologies shares fell 2.9% to $150.98 late Friday, underperforming chip equipment peers as the iShares Semiconductor ETF was flat and Applied Materials and Lam Research gained. No new operating news was released, with recent filings limited to insider stock changes. Investors are watching for updates on memory-chip demand and the Veeco Instruments deal. Axcelis expects Q2 revenue near $205 million and non-GAAP EPS around 90 cents.
AirSculpt Shares Slip as June Investor Test Looms
AirSculpt Technologies shares fell 2.9% to $5.38 Friday, trailing small-cap peers ahead of two June investor events where executives aim to defend the company’s outlook. First-quarter revenue was flat at $39.4 million, with net loss narrowing to $2.4 million. The company raised $14.6 million in a share sale this quarter, using most to pay down debt. Investors remain focused on management’s response to weight-loss drug competition.
Enveric Biosciences Stock Slips as Cash Questions Hang Over ENVB
Enveric Biosciences closed at $2.30 on Nasdaq Friday, down 0.86%, with a market cap near $8.5 million. The company’s last update was a May 19 release on preclinical safety data for EB-003. Its Q1 filing warned current cash won’t cover 12 months of operations. Enveric remains preclinical and has not announced new funding or product approvals.
JAKKS Pacific Dips as Dividend Date Draws Attention
JAKKS Pacific shares fell 3.1% to $22.16 Friday after trading ex-dividend, lagging Mattel and Hasbro. First-quarter net sales dropped 6% to $106.7 million, with a net loss of $4.3 million, or 37 cents per share. International sales rose 38% to $29 million, offsetting weaker North America demand. The company’s 25-cent dividend is payable June 29 to holders as of May 29.
J.B. Hunt Near 52-Week High as Freight Names Draw Moves
J.B. Hunt shares rose 1.1% to $275.38 Friday, nearing a 52-week high and lifting its market cap to about $26.2 billion. The stock is up 6.4% from the prior Friday’s close, boosted by investor hopes for better freight pricing and margins. J.B. Hunt reported Q1 revenue of $3.06 billion and EPS of $1.49. The company’s intermodal unit saw eastern network loads rise 7% as more freight shifted to rail.
Pharvaris Trades Flat as Investors Wait for June Data Update
Pharvaris shares edged up 0.5% to $30.00 on Nasdaq Friday after the company announced new clinical data on its hereditary angioedema drug deucrictibant will be presented at a major allergy conference in June. The company plans a U.S. filing for the drug’s immediate-release capsule in the first half of 2026 and expects Phase 3 prevention data in the third quarter.
Orchestra BioMed Shares Trade Lower Ahead of Trial Milestone
Orchestra BioMed shares fell 0.8% to $3.95 Friday afternoon, underperforming the SPDR S&P Biotech ETF’s 0.4% gain. The company expects to finish enrollment for its BACKBEAT pivotal trial by the end of Q3 2026. Management will appear at the Jefferies Global Healthcare Conference on June 4. Cash holdings stood at $94.4 million at the end of March, with an additional $35 million received in May.
Alliant Energy Shares Fall Again as Investors Watch Data-Center Power Plays
Alliant Energy shares fell 0.9% to $71.50 Friday afternoon, deepening Thursday’s 2.1% drop. The stock is now 4.7% below its May 1 high. Utilities lagged, with WEC Energy and Xcel Energy also down. Alliant’s 2026 earnings target and data-center deals remain unchanged.
Marriott Hits 52-Week High as Wall Street Watches the Move
Marriott shares fell about 3% to $374.28 Friday afternoon, erasing gains from earlier in the week despite U.S. indexes hitting new highs. The stock lagged peers after reaching a 52-week high Wednesday. Investors cited valuation concerns, Middle East exposure, and weaker hotel sector performance. Market cap stood near $98.6 billion.
vTv Therapeutics Drops as Diabetes Study Date Approaches
vTv Therapeutics shares fell 1.1% to $33.14 Friday afternoon, underperforming biotech indexes as investors await updates on its diabetes drug cadisegliatin. The company last reported on May 13, saying Phase 3 CATT1 enrollment remains on track for Q3 2026. Cash reserves rose to $98.1 million at March 31 after a $20 million licensing payment. No new filings or press releases have been issued since the quarterly report.
Northrim BanCorp (NRIM) Stock Ticks Up After $0.16 Dividend — The Small-Bank Signal to Watch
Northrim BanCorp shares rose 0.2% to $24.80 Friday after the Alaska bank declared a $0.16 per share quarterly dividend, payable June 18 to holders as of June 11. The bank reported first-quarter net income of $13.7 million and a net interest margin of 4.77%. Nonperforming assets increased to $15.3 million at March 31 from $11.4 million at year-end. Market value stood near $560 million.
Launchpad Cadenza Shares Static With $232M Trust Backing
Launchpad Cadenza Acquisition Corp I Class A shares traded at $10.01 midday Friday on Nasdaq, up 0.4% with 929 shares in volume. The SPAC’s trust account held $232.3 million as of March 31, with shares carrying a $10.10 redemption value. Launchpad reported $1.73 million net income for the first quarter, all from interest. The company has not selected a merger target.
Bloomia Dips as Debt Maturity Hangs Over TULP
Bloomia Holdings shares fell 1.7% to $3.86 in light Nasdaq trading Friday, staying below the $4.05 rights offering price from April. The company faces a May 27 deadline to pay a seller note after recent filings flagged covenant issues. Bloomia posted a March-quarter net loss of $765,000 despite higher revenue. Gross margin dropped to 19.8% from 31.3% a year earlier.
YXT.com up 17% after Nasdaq deadline brings AI SaaS company back to focus
YXT.COM Group Holding Ltd shares rose 17% to $0.50 in light Nasdaq trading Friday, despite no new company news. The stock remains below Nasdaq’s $1 minimum bid and faces a July 27 deadline to regain compliance. YXT reported a wider 2025 net loss and falling subscriber numbers in April. Trading volume reached 29,440 shares, with prices ranging from $0.443 to $0.5199.
CVB Financial Shares Trade Higher Ahead of Heritage Deal, General Counsel Departure
CVB Financial shares rose 0.3% to $20.48 Friday after announcing General Counsel Richard Wohl will retire June 5, with accelerated equity vesting worth about $364,000. The company closed its Heritage Commerce merger April 17, pushing assets above $20 billion. First-quarter net income was $51 million, down from $55 million in Q4. Regional bank stocks traded mixed.
Aurinia Stock Dips as Traders Eye Lupkynis Data
Aurinia Pharmaceuticals shares fell 0.9% to $15.21 in late morning Nasdaq trading Friday, underperforming the broader biotech sector. Investors focused on Lupkynis sales and the upcoming June 3 shareholder meeting, with no new company news released. The company relies on Lupkynis as its only approved drug and faces competition from GSK’s Benlysta and Genentech’s Gazyva.
Newegg Stock Slides After Profit Swing as Sales Drop Tests the PC-Hardware Retailer
Newegg shares dropped 5.4% to $17.60 after first-quarter net sales fell 11.8% to $306.2 million and gross merchandise value slipped 12.1%. The company posted a $7.8 million profit, reversing a loss last year, as gross profit rose 10.3%. Active customers and repeat purchase rates declined. Management cited memory shortages and cautious consumer demand.
Northwest Bancshares Stock Nears 52-Week High After Insider Buy Puts NWBI Back In Focus
Northwest Bancshares shares rose 1.1% to $14.22 midday Friday after a regulatory filing showed director Timothy M. Hunter bought 10,000 shares earlier in the week. The stock traded near its 52-week high of $14.26. Northwest reported Q1 net income of $51 million and a 20-cent dividend. The KBW Nasdaq Regional Banking Index was up 0.35%.
Taylor Devices Stock Slips as Investors Eye Backlog Despite Record Sales
Taylor Devices shares fell 3.9% to $51.60 in light Nasdaq trading Friday, bucking gains across major U.S. indexes. The company reported record nine-month sales but a backlog of $20.8 million, down from $33.3 million a year earlier. Aerospace and defense accounted for 66% of recent sales, up from 58%. Structural and industrial demand remained weak.